Iniparib

4- iodo-3 - nitrobenzamide

Template: Infobox chemical / molecular formula search available

Iniparib (former name: BSI 201 Manufacturer: Sanofi- Aventis) is a substance that the DNA -repairing protein PARP -1 ( enzyme) irreversibly inhibited. It was in clinical trials for the treatment of various cancers, such as in lung cancer and the so-called triple receptor- negative breast cancer (triple -negative breast cancer, TNBC ).

The first promising results in terms of progression- free survival and overall survival after treatment for iniparib with triple receptor- negative breast cancer could not be confirmed in a large phase III study. Therefore Sanofi stopped in 2013, the development of the compound. This has cost the company about € 219 million.

Areas of application

Iniparib is an anti- tumor agent with a poly (ADP -ribose) polymerase (PARP ) inhibiting activity. The enzyme PARP is an important regulator for the repair of DNA damage. By inhibiting PARP to repair DNA damage is prevented or made ​​more difficult.

Side effects

Side effects include neutropenia, anemia, thrombocytopenia, asthenia, nausea and constipation.